SOURCE: BioCentury; Thomson Reuters

BioCentury; Thomson Reuters

April 15, 2011 05:00 ET

Thomson Reuters and BioCentury Today Convene Future Leaders in the Biotech Industry

44 Companies Offer Differentiated Products, Upcoming Milestones and Partner-Ready Assets

NEW YORK, NY--(Marketwire - Apr 15, 2011) - BioCentury and Thomson Reuters today convene the 18th Annual FutureLeaders in the Biotech Industry conference in New York City with a program to showcase fresh opportunities for biotech stocks. The event features 44 biopharma companies independently selected for their upcoming news flow and ability to attract capital and to offer unpartnered compounds to pharma deal makers.

The conference, which has pre-registered more than 700 key life science investors and pharmaceutical licensing professionals, starts at 8 a.m. today at the Millennium Broadway Hotel & Conference Center in New York.

Public companies at Future Leaders collectively are up 50% over the past year, easily out-distancing the 20% jump in the BioCentury 100 Index and the 13% gain in the S&P 500 and the Dow Jones Industrial Average. Over that same period, the aggregate market cap of the Future Leaders public companies has grown by almost $2 billion, from $3.6 billion to $5.4 billion.

The Future Leaders Class of 2011 includes 27 public and 17 private companies that have raised $6 billion in capital, including $1.5 billion since the beginning of 2010.

These Future Leaders have 22 marketed products, including 11 therapeutics and 4 diagnostics, 17 programs in Phase III, 51 programs in Phase II and 46 programs in Phase I development. The companies have at least 70 programs in preclinical development, including 58 that are currently unpartnered.

The disease space covers cancer, infectious diseases, metabolic and autoimmune disorders. This year's class also includes a group of commercially-minded diagnostic plays and companies developing bio-defense assets.

"Investors are hoping for a boost from high profile biotech product launches, along with plenty of clinical and regulatory news flow in the second quarter," said David Flores, BioCentury's President & CEO. "As BioCentury reported in its 2Q Financial Markets Preview this month, the biotech sector is hoping to continue its surge at the end of the first quarter, when public biotechs raised $11.9 billion, the strongest performance of any quarter since 1Q 2000."

Money managers attending the conference control $800 million in equity assets, $79 billion in healthcare assets, and $21 billion in biotech assets.

The2011 Presenting Companies

Presenting companies were screened using Thomson Reuters and BioCentury industry analysis and proprietary databases, including BioCentury's BCIQ online business intelligence platform. The result is an independently selected mix of companies with proven fundraising capacity, the prospect for key partnerships and proximity to potentially transformational milestones. (Stock symbols shown for publicly traded companies; listed on NASDAQ unless noted).

Acceleron Pharma Inc.
Achillion Pharmaceuticals Inc. (ACHN)
Algeta ASA (ALGETA) -- traded on OSE
ArQule Inc. (ARQL)
Avanir Pharmaceuticals Inc. (AVNR)
AVI BioPharma Inc. (AVII)
BG Medicine Inc. (BGMD)
Biolex Therapeutics Inc.
BioSante Pharmaceuticals Inc. (BPAX)
BioSpecifics Technologies Corp. (BSTC)
Cempra Pharmaceuticals Inc.
ChemoCentryx Inc.
Chimerix Inc.
Complete Genomics Inc. (GNOM)
Curis Inc. (CRIS)
Cytori Therapeutics Inc. (CYTX; XMPA) -- XMPA traded on Xetra
Elevation Pharmaceuticals Inc.
Endoycte Inc. (ECYT)
Enobia Pharma Inc.
Epigenomics AG (ECX) -- traded on Xetra
Epizyme Inc.
Euthymics Bioscience Inc.
Five Prime Therapeutics Inc.
Infinity Pharmaceuticals Inc. (INFI)
Invida Group Pte. Ltd.
iPierian Inc.
Omeros Corp. (OMER)
Pacira Pharmaceuticals Inc. (PCRX)
PharmAthene Inc. (PIP) -- traded on NYSE-A
Pieris AG
Progenics Pharmaceuticals Inc. (PGNX)
Repligen Corp. (RGEN)
Rib-X Pharmaceuticals Inc.
RXi Pharmaceuticals Corp. (RXII)
S*BIO Pte. Ltd.
SuperGen Inc. (SUPG)
Synta Pharmaceuticals Corp. (SNTA)
Threshold Pharmaceuticals Inc. (THLD)
Transcept Pharmaceuticals Inc. (TSPT)
Trius Therapeutics Inc. (TSRX)
Versartis Inc.
Xoma Ltd. (XOMA)
Zafgen Inc.
Ziopharm Oncology Inc. (ZIOP)

See the Presenting Company schedule and additional program highlights

Top Sponsors Demonstrate Long-Term Commitment to Industry

Anchored by Gold Sponsor Hogan Lovells, the prestigious group of 2011 sponsors includes leaders from both the public and private capital markets: Ladenburg Thalmann, OrbiMed Advisors, Rodman & Renshaw, Torreya Partners, WBB Securities and Yorkville Advisors.

This premier Wall Street event is one of two annual investor conferences organized by BioCentury and Thomson Reuters. The next conference, NewsMakers in the Biotech Industry, will take place in New York City on October 21, 2011, at the Millennium Broadway Hotel & Conference Center.

About BioCentury
BioCentury Publications, Inc. provides essential biopharma industry intelligence from five offices in the U.S. and Europe. For more than 18 years, a global audience of biotech and pharmaceutical executives and investors has benefited from BioCentury's deep knowledge, data-driven analysis, independent perspective and trustworthy content available through the company's publications, data products and collaborative industry conferences in the U.S., Europe and Asia. BioCentury's titles include the flagship BioCentury®, the Bernstein Report on BioBusiness; its SciBX: Science-Business eXchange™ translational science joint publishing venture with Nature Publishing Group; and its BioCentury Extra™ online daily newspaper. These timely journals are backed by BCIQ: BioCentury Online Intelligence™, an online business intelligence resource. Through a partnership with the Gannett-owned WUSA9 CBS affiliate in Washington, D.C., BioCentury produces BioCentury This Week biotech public affairs program each Sunday, part of the WUSA9 CBS "Sunday Morning Power Block." For more information, visit and

About Thomson Reuters
Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, healthcare and science and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs 55,000 people and operates in over 100 countries. For more information, go to

Contact Information

    Thomas C. Carey
    Vice President of Commercial Operations
    BioCentury Publications, Inc.
    +1 650 595-5333
    Email: Email Contact